Checkmate Pharmaceuticals, Inc. (CMPI) SEC Filing 8-K Material Event for the period ending Tuesday, December 14, 2021

Checkmate Pharmaceuticals, Inc.

CIK: 1651431 Ticker: CMPI

View differences made from one to another to evaluate Checkmate Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Checkmate Pharmaceuticals, Inc..


Assess how Checkmate Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Checkmate Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Checkmate Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CMPI
CIK: 1651431
Form Type: 8-K Corporate News
Accession Number: 0001193125-21-356927
Submitted to the SEC: Tue Dec 14 2021 5:22:10 PM EST
Accepted by the SEC: Tue Dec 14 2021
Period: Tuesday, December 14, 2021
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. Other Events
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: